Searchable abstracts of presentations at key conferences in endocrinology

ea0034p263 | Obesity, diabetes, metabolism and cardiovascular | SFEBES2014

Renalase a key regulator of brown adipose tissue activity

Ramanjaneya Manjunath , Tan Bee , Patel Vanlata , Hu Jiamiao , Lehnert Hendrik , Hillhouse Edward , Chen Jing , Randeva Harpal

Renalase is a recently discovered flavin adenine dinucleotide (FAD)-dependent oxidase, predominantly secreted into the circulation from the kidney and regulates catecholamine degradation and metabolism. Renalase gene is also present in heart muscle, skeletal muscle and liver cells in humans, and in mouse testicles. Four isoforms of renalase gene has been identified in humans (hRenalase1 to hRenalase4), however only hRenalase1 is detected in human blood suggesting that hRenalas...

ea0070aep112 | Adrenal and Cardiovascular Endocrinology | ECE2020

A patient with seizures and adrenal failure as systemic manifestations of miliary tuberculosis: A case report

Jugnarain Davina , Patel Shirin , Mahamud Bashir , Reddy Kotha Swetha , Mlawa Gideon

Introduction: Extrapulmonary manifestations of tuberculosis can cause a diverse range of atypical presentations, depending on the system involved. Involvement of lymph nodes, pleura, central nervous system and bone are some of the organs that are well-described in the literature. This leads to a diverse range of presentations which can misguide diagnosis unless there is a high index of suspicion. Endocrinological manifestations are rare, but can occur uponhaematogenous dissemi...

ea0070ep291 | Pituitary and Neuroendocrinology | ECE2020

Cabergoline treatment: The ethics around side effects

Ratnasabapathy Risheka , Patel Bijal , Qayum Ambreen , Zaman Shamaila , Behary Preeshila , Meeran Karim , Martin Niamh

Cabergoline has long been used to treat prolactinomas for symptomatic, radiological and biochemical resolution of pituitary tumours. As clinicians we are well-versed at screening for physical side effects, but are we holistic enough? We present two cases illustrating the damaging social consequences of cabergoline treatment for prolactinomas.Case 1A 49-year-old married father of two presented with a seizure in April 2018. MRI showe...

ea0031p56 | Clinical biochemistry | SFEBES2013

Audit of inpatient management of hyponatraemia

Patel Bhavin , Coyle Gillian , Srinivas Vidya , Gomez Javier , Myint Khin Swe

Introduction: Hyponatraemia is the commonest electrolyte disturbance occurring in 15–20% of inpatients (1), with significant clinical implications if mismanaged. We conducted a retrospective audit of our current management of hyponatraemia in our 1000 bedded trust.Method: Data of patients with severe hyponatraemia (Na<125 mmol/l) admitted to hospital over 4 weeks (Aug 2011) was collected. Twenty randomly selected cases were reviewed focusing on ...

ea0031p166 | Neoplasia, cancer and late effects | SFEBES2013

Difficulties in management of malignant insulinoma

Garg A , Rathore A M , Patel D C , Khoo B , Caplin M , Meyer T

Introduction: Insulinomas are the most common, functioning, pancreatic neuro-endocrine tumours. The minority of patients <10% who present with metastatic disease have a median survival of <2 years.We present a case of a gentleman with a 30 years history of Multiple Endocrine neoplasia type 1 (MEN1), which highlights the various modalities of treatment and the challenges from his progressive disease and marked symptomatic hypoglycaemia.<p clas...

ea0028p343 | Thyroid | SFEBES2012

Evaluation of adjuvant lithium treatment in patients receiving radioactive iodine for hyperthyroidism: a retrospective cohort study

Patel Miraj , Nijher Gurjinder , Misra Shivani , Murphy Elaine , Meeran Karim , Martin Niamh

Lithium increases retention of Iodine-131 in the thyroid gland and inhibits thyroid hormone release following radioactive iodine (RAI) administration. However, outcomes of studies of the effects of lithium on the efficacy of RAI are conflicting. The aim of this study was to assess whether adjuvant lithium increases the efficacy of RAI treatment in hyperthyroidism. A retrospective cohort study was performed of 204 hyperthyroid patients (163 Graves’ disease, 26 toxic multin...

ea0027p77 | (1) | BSPED2011

Octreotide treatment for congenital hyperinsulinism can cause hepatitis

Avatapalle Bindu , Rigby Lindsey , Patel Leena , Ehtisham Sarah , Skae Mars , Padidela Raja , Banerjee Indraneel , Clayton Peter

Introduction: Congenital hyperinsulinism (CHI) is a rare condition of dysregulated insulin secretion causing hypoglycaemia. Oral Diazoxide is used as first line therapy for CHI. In those who are Diazoxide unresponsive, subcutaneous Octreotide is used as second line treatment. Octreotide has recognised side effects of biliary stasis. Additionally, we report hepatitis as a complication of Octreotide therapy in a child with CHI.Case report: A neonate with C...

ea0027p81 | (1) | BSPED2011

An audit of diazoxide prescriptions in children with congenital hyperinsulinism: preliminary recommendations

Dimitriu Alma Iulia , Avatapalle Bindu , Rigby Lindsey , Banerjee Indraneel , Patel Leena

Introduction: Congenital hyperinsulinism (CHI) is characterised by abnormally regulated and excessive insulin secretion by pancreatic β cells. First line management includes an oral suspension of Diazoxide but a standardised formulation is not universally employed. Anecdotal evidence suggests that different formulations can alter the management of glucose levels. Lack of glucose control can lead to permanent brain damage and adversely affect neuro development.<p class...

ea0026p24 | Adrenal cortex | ECE2011

Hormones failing the heart

Pierides M , Cullen J , Al-Hamali S , Patel K , O'Malley B

Cardiovascular disease and diastolic hypertension are major causes of morbidity in Cushing’s although left ventricular failure is more rarely described. There are three other cases of documented dilated cardiomyopathy with subsequent left ventricular failure.Thirty-five year old lady who presented with obesity and striae was found to have a suppressed ACTH, elevated cortisol (914 post dexamethasone suppression test) and a right adrenal adenoma (on C...

ea0025oc1.7 | Young Endocrinologists prize session | SFEBES2011

Mutant cytochrome b5 causing 46,XY disorder of sex development (DSD) due to apparent CYP17A1 17,20 lyase deficiency

Idkowiak Jan , Randell Tabitha , Dhir Vivek , Patel Pushpa , Shackleton Cedric H L , Krone Nils , Arlt Wiebke

In humans, androgen synthesis crucially depends on the enzyme CYP17A1 expressed in adrenals and gonads. The 17,20 lyase activity of CYP17A1 catalyses the key step in human androgen biosynthesis, the conversion of 17-hydroxypregnenolone to the universal sex steroid precursor dehydroepiandrosterone (DHEA). For its catalytic activity, CYP17A1 requires electron transfer from P450 oxidoreductase (POR). Mutations in CYP17A1 and POR are known to disrupt human androgen s...